Streetbeat News

Equity Actions

PARA

Skydance has proposed a revised deal to merge with Paramount, offering a $3 billion cash infusion to help pay down debt and buy back stock. This move aims to appease investors and secure a merger with Paramount, which has been under consideration for sale by its controlling shareholder, Shari Redstone. The investment would come from RedBird and David Ellison's family, enhancing the terms for Paramount shareholders.

Portfolio Pulse from Benzinga Newsdesk

April 29, 2024 | 3:45 pm

FULT

Fulton Financial announced in a conference call that it plans to sell a $2 billion securities portfolio of Republic Bank.

Portfolio Pulse from Benzinga Newsdesk

April 29, 2024 | 3:12 pm

FULT

Fulton Financial announced in a conference call that it expects to receive $1 billion from the Federal Deposit Insurance Corporation (FDIC) as part of a transaction.

Portfolio Pulse from Benzinga Newsdesk

April 29, 2024 | 3:11 pm

VINC

Vincerx Pharma's shares are trading higher after the company announced a proposed underwritten public offering of common stock and warrants, reversing earlier losses.

Portfolio Pulse from Benzinga Newsdesk

April 29, 2024 | 3:04 pm

ABBV

AbbVie (NYSE:ABBV) received mixed analyst ratings in the latest quarter, with an average 12-month price target of $189.75, reflecting a positive shift from the previous $184.00. Analysts' actions varied, with some raising and others lowering their price targets, indicating differing views on AbbVie's market performance. Despite this, AbbVie faces financial challenges, including a -5.42% decline in revenue growth and below-average profitability metrics, suggesting potential short-term investment risks.

Portfolio Pulse from Benzinga Insights

April 29, 2024 | 3:01 pm

AVB

AvalonBay Communities (NYSE:AVB) has been the subject of diverse analyst ratings over the last three months, with a recent shift towards more bullish sentiments. The latest analysis shows an average 12-month price target of $198.75, marking a 2.37% increase from the previous target. Analysts from firms like RBC Capital, Piper Sandler, Truist Securities, Mizuho, Morgan Stanley, Goldman Sachs, and Barclays have updated their ratings and price targets, reflecting various adjustments based on the company's performance and market conditions. AvalonBay Communities, with a significant portfolio of apartment communities, has shown impressive financial metrics such as a 5.23% revenue growth rate, a net margin of 34.1%, and strong ROE and ROA figures, indicating robust financial health and market presence.

Portfolio Pulse from Benzinga Insights

April 29, 2024 | 3:00 pm

MSFT

The article provides an in-depth competitor analysis of Microsoft (NASDAQ:MSFT) and its position within the Software industry, comparing financial metrics like P/E, P/B, P/S ratios, ROE, EBITDA, gross profit, and revenue growth against its major competitors. Microsoft shows potential for growth with a reasonable P/E ratio, suggests undervaluation with its P/B ratio, but its P/S ratio could indicate overvaluation. Its ROE is below the industry average, yet it has significantly higher EBITDA and gross profit, indicating strong profitability. The company's revenue growth outpaces the industry average, suggesting a positive outlook.

Portfolio Pulse from Benzinga Insights

April 29, 2024 | 3:00 pm

ATXI

Avenue Therapeutics (NASDAQ:ATXI) stock fell by 20.7% to $4.92 after announcing the exercise of warrants for $4.4 million in gross proceeds at a reduced price of $6.20 per share. The company will issue new Series C and D warrants as part of the transaction, expected to close by May 1, 2024. ATXI's stock has significantly declined over the past year, with a 93.29% decrease, and is currently considered oversold with an RSI of 27.91.

Portfolio Pulse from Henry Khederian

April 29, 2024 | 2:59 pm

ZVSA

ZyVersa Therapeutics, Inc. (NASDAQ:ZVSA) shares surged after announcing the publication of a scientific paper in 'Frontiers in Molecular Neuroscience'. The paper, authored by researchers from the University of Miami Miller School of Medicine, supports the use of ZyVersa's IC 100 to potentially reduce cardiac issues in Alzheimer's patients by inhibiting ASC inflammasomes. Additionally, ZyVersa executed a 1-for-20 reverse stock split last Friday, resulting in a float of less than 758,000 shares. The company does not pay dividends but engages in other capital allocation strategies.

Portfolio Pulse from Erica Kollmann

April 29, 2024 | 2:53 pm

AIU

Meta Data's (NYSE:AIU) short interest has decreased by 40%, now representing 0.03% of its float with 24 thousand shares sold short. It would take about 3.23 days to cover these short positions. This decline in short interest could indicate a more bullish sentiment towards the stock, contrasting with the peer group average of 2.51% short interest.

Portfolio Pulse from Benzinga Insights

April 29, 2024 | 2:30 pm